Adrenaline

ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is currently EVP, Corporate, Portfolio & Product Strategy (CPPS) and has been a member of the Executive Leadership Team since 2024. Prior to this, he headed up ALK’s commercial operations in international markets. With more than 25 years of pharmaceutical, business development, and research experience, a PhD in vaccine development and immunology, and a Master’s degree in Biochemistry, Jacob Glenting brings a combination of scientific expertise and commercial acumen. This background makes him well suited to advance ALK’s R&D efforts according to the Allergy+ strategy by balancing innovation to support core-business growth with expansion into adjacent allergy therapy areas via internal pipeline activities, partnerships, and business development & licensing. Since joining ALK in 2007, Jacob Glenting has worked at the interface between commercial and science. He has played a key role in several of ALK’s strategic developments, including the partnerships with Torii (now Shionogi) in Japan, Abbott in Southeast Asia, GenSci in China, and the licensing agreement for neffy ® with ARS. He has also been deeply involved in ALK’s paediatric expansion, corporate strategy, business development, and the therapeutic area setup. President & CEO Peter Halling said: “Jacob brings significant contributions to ALK and has been instrumental in our strategic partnerships. His scientific background combined with his strong experience in ALK and ability to connect our R&D and commercial strategy, makes him uniquely qualified to drive our innovation strategy. I am confident that he will be able to continue to grow ALK’s pipeline, strengthen our therapeutic areas, and expand our business through partnerships.” Jacob Glenting said: “Throughout my career, I have been deeply committed to allergy and ALK, and I’m honoured to take on the role of leading the R&D organisation . T he company has a strong scientific heritage and a pipeline with real potential to address significant unmet medical needs. My focus will be on advancing ALK’s pipeline with scientific rigour and discipline while also drawing on our partners’ knowledge and capabilities. I look forward to working with the talented teams across the organisation and with our partners to ensure that our innovation ultimately delivers benefits to patients and prescribers.” Following the appointment, ALK’s Executive Leadership Team consists of: Peter Halling, President & CEO Claus Steensen Sølje, EVP & CFO Jacob Glenting, EVP, Global R&D Christian G. Houghton, EVP, Product Supply Flora Beiche-Scholz, EVP, Commercial Operations Europe Edward Jordan, EVP, Commercial Operations North America Lika Thiesen, EVP, Global People & Organisation Jan Engel, SVP, Global Quality ALK-Abelló A/S For further information please contact: Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media : Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at . Attachment Press release_20August26_Appointment Head of R&D

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer. “I have known Eyal for over a decade and have always admired his contributions in any role,” said Brendan O’Grady, Chief Executive Officer of Nasus. “While I am disappointed that Eyal will be leaving Nasus, I am excited for him as he takes on a new challenge and opportunity. I appreciate his commitment to a seamless transition and look forward to working with him over the next several weeks. I also congratulate Oren Elmaliach as he assumes the role of Interim Chief Financial Officer. I have full confidence in Oren as he knows the Company exceptionally well and will provide important continuity as Nasus continues to move forward.” “Eyal has made meaningful contributions to Nasus, playing an important role in our transition as a public company and in building the financial foundation for our next stage of development,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “We understand and fully support his decision to pursue this important next step in his career. On behalf of the Board and the entire Nasus team, I want to thank Eyal for his contributions, professionalism, and partnership and wish him every success in this next chapter.” Mr. Elmaliach has been with Nasus since its inception and has extensive knowledge of the Company’s financial operations, reporting processes and organization. A certified public accountant, Mr. Elmaliach brings more than 15 years of financial experience and leadership including significant experience supporting public and private life sciences companies and working within the US public markets and financial reporting environment. About Nasus Pharma Nasus Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company's lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the timing of the chief financial officer role transition. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on current expectations and and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, andhe Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law. Company Contact Nasus Pharma Ltd. info@nasuspharma.com Investor Contact Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com